Literature DB >> 12537938

Novel concepts in the staging of renal cell carcinoma.

Dan Leibovici1, Arie Lindner, Avishay Sella, Amnon Zisman.   

Abstract

The incidence of renal cell carcinoma (RCC) continues to rise steadily; unfortunately, our ability to cure patients with metastatic RCC remains limited. When developing and evaluating new treatment protocols, it is important to consider the role of prognostic factors, often defined as pretreatment features, that are predictive of outcome. The complexity and variability of patients' individual clinical outcome and the recently recognized limitation of conventional staging systems have lead to the formulation of integrated prognostic staging systems. In this review, we discuss the evolution of various clinically relevant integrated staging systems for RCC.

Entities:  

Mesh:

Year:  2003        PMID: 12537938     DOI: 10.1007/s11934-003-0056-5

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   2.862


  54 in total

1.  Serum acute phase reactants and prognosis in renal cell carcinoma.

Authors:  B Ljungberg; K Grankvist; T Rasmuson
Journal:  Cancer       Date:  1995-10-15       Impact factor: 6.860

2.  Cancer statistics, 2000.

Authors:  R T Greenlee; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  2000 Jan-Feb       Impact factor: 508.702

3.  Guidelines on renal cell cancer.

Authors:  G Mickisch; J Carballido; S Hellsten; H Schulze; H Mensink
Journal:  Eur Urol       Date:  2001-09       Impact factor: 20.096

4.  Clinical significance of angiogenesis, proliferation and apoptosis in renal cell carcinoma.

Authors:  S Yoshino; M Kato; K Okada
Journal:  Anticancer Res       Date:  2000 Jan-Feb       Impact factor: 2.480

5.  Prognostic factors in renal-cell carcinoma: immunohistochemical detection of p53 protein versus clinico-pathological parameters.

Authors:  F J Bot; J C Godschalk; K K Krishnadath; T H van der Kwast; F T Bosman
Journal:  Int J Cancer       Date:  1994-06-01       Impact factor: 7.396

6.  Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma.

Authors:  D L Uhlman; P L Nguyen; J C Manivel; D Aeppli; J M Resnick; E E Fraley; G Zhang; G A Niehans
Journal:  J Natl Cancer Inst       Date:  1994-10-05       Impact factor: 13.506

7.  Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha.

Authors:  S D Fosså; A Kramar; J P Droz
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

Review 8.  Renal cell carcinoma: comparison of the TNM and Robson stage groupings.

Authors:  P Guinan; R Saffrin; D Stuhldreher; W Frank; M Rubenstein
Journal:  J Surg Oncol       Date:  1995-07       Impact factor: 3.454

9.  Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2.

Authors:  P A Palmer; J Vinke; T Philip; S Negrier; J Atzpodien; H Kirchner; R Oskam; C R Franks
Journal:  Ann Oncol       Date:  1992-06       Impact factor: 32.976

10.  Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma.

Authors:  F Wittke; R Hoffmann; J Buer; I Dallmann; K Oevermann; S Sel; T Wandert; A Ganser; J Atzpodien
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.